Incyte, a Delaware-founded global biopharmaceutical company with a portfolio of treatments across oncology, inflammation and autoimmunity, has chosen downtown Wilmington, Delaware, for its new headquarters.
 
It will renovate two buildings in downtown Wilmington, whose 517,307 square feet will almost double the company’s Delaware footprint. The new space will allow Incyte to continue building its Delaware employee base by bringing in more than 300 employees currently working in Chadds Ford, Pennsylvania, and provide space to grow and add more than 500 new positions across the two buildings in the future.
  
Expanding its offices to downtown Wilmington will create numerous benefits for Incyte. Vacated office space at the Alapocas campus will be converted into much-needed lab space and will accommodate the company’s projected future growth.
  
“Delaware has been our home for more than 20 years, and we are looking forward to expanding our operations in Wilmington and continuing to grow our company here,” said Incyte Chief Executive Officer Hervé Hoppenot. “We are grateful to the continued support of the state, the city and others, including DPP, who have supported our company and fostered innovation and growth in our region.”